Ann: Trading Halt, page-46

Let's hope so @mcexplorer. I really hope this deal (i.e., assuming it is with AZ or another big pharma) comes with plans or funding to examine the efficacy of Exenatide/Presendin study in another population (e.g., COVID). I understand that over the next few months we need to focus on IIH patients, sort out the EMA/FDA pathway, and progress the Phase 3 trial(s), but at the moment it's an all or nothing scenario. We need to increase our pipeline to de-risk, improve the value proposition, and get buy in + publicity + interest from the wider market. One step at a time I guess